Top-News

Neumora Therapeutics Aktie News

Aktie
WKN:  A3EVX4 ISIN:  US6409791000 US-Symbol:  NMRA Branche:  Biotechnologie Land:  USA
2,22 $
-0,055 $
-2,42%
1,9066 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
368,40 Mio. €
Streubesitz
17,74%
KGV
-7,02
Index-Zuordnung
-

Neumora Therapeutics News

14.02.25 - PR Newswire
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - Contact Kessler Topaz Meltzer & Check, LLP
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - Contact Kessler Topaz Meltzer & Check, LLP PR Newswire
14.02.25 - PR Newswire
Neumora Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United ...
14.02.25 - PR Newswire
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire
13.02.25 - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics PR Newswire
13.02.25 - PR Newswire
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
13.02.25 - PR Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
12.02.25 - PR Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm PR Newswire
11.02.25 - PR Newswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class ...
11.02.25 - PR Newswire
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire
10.02.25 - PR Newswire
Investor Alert: Robbins LLP Informs Investors of the Neumora Therapeutics, Inc. Class Action
Investor Alert: Robbins LLP Informs Investors of the Neumora Therapeutics, Inc. Class Action PR Newswire
09.02.25 - PR Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm PR Newswire
07.02.25 - PR Newswire
NMRA INVESTOR ALERT: Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NMRA INVESTOR ALERT: Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »